NORDIC GROUP BV - search results

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teysuno 20mg5.8mg15.8mg capsules

nordic pharma ltd - tegafur; gimeracil; oteracil potassium - capsule - 20mg ; 5.8mg ; 15.8mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teysuno 15mg4.35mg11.8mg capsules

nordic pharma ltd - tegafur; gimeracil; oteracil potassium - capsule - 15mg ; 4.35mg ; 11.8mg

European Union - English - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - stomach neoplasms - antineoplastic agents - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1).- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nordimet 7.5mg0.3ml solution for injection pre-filled pens

nordic pharma ltd - methotrexate - solution for injection - 25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nordimet 10mg0.4ml solution for injection pre-filled pens

nordic pharma ltd - methotrexate - solution for injection - 25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nordimet 12.5mg0.5ml solution for injection pre-filled pens

nordic pharma ltd - methotrexate - solution for injection - 25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nordimet 15mg0.6ml solution for injection pre-filled pens

nordic pharma ltd - methotrexate - solution for injection - 25mg/1ml